Skip to main content

Table 2 Costs for specific direct cost components

From: A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies

Study Country Study period Cost component Population Sample size Mean cost (2020 USD) GDP per capita
(2020 USD)
Proportion of GDP per capita (%)
Yu [50] US 2006–2011 Hospitalization IPF 1735 16,205 57,395 28
Mooney [51] US 2009–2011 Hospitalization IPF 22,350 19,136 57,395 33
Fan [52] US 2014–2016 Hospitalization IPF 300 15,202 62,567 24
Cottin [53] France 2008–2013 Hospitalization IPF 6476 5410 47,333 11
Navaratnam [54] England 1998–2010 Hospitalization IPF 26,766 2964* 46,927 6
Pedraza-serra [55] Spain 2004–2013 Hospitalization IPF 12,739 7886 32,294 24
Hernandez-Gomez [56] Spain 2011–2014 Cryobiopsy Fibrotic ILD 33 472 32,252 1
  1. The proportion of GDP per capita represents the mean annual cost per patient relative to the country’s GDP per capita based on 2020 USD [12]. The cost per hospitalization or cryobiopsy procedure is shown. *cost per number of bed days. Median value of first hospitalization. Abbreviations: GDP, gross domestic product; IPF, idiopathic pulmonary fibrosis